SMCs With LVH Compared to HCM

Active, not recruiting

• Conditions: Syndromic and Metabolic Cardiomyopathy; Hypertrophic Cardiomyopathy (HCM)

• Registration Number: NCT07006974
• Lead Sponsor: China National Center for Cardiovascular Diseases

Brief Summary

The goal of this cohort study is to investigate the clinical characteristics of SMCs and to explore the difference in cardiovascular outcomes in comparison to age-, sex-, and admission year-matched HCM patients. The main question it aims to answer is:

* Do patients with SMCs have higher rates of cardiac outcomes?

* What risk factors do SMCs patients experience a poor prognosis?

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-05
• Study Start: 2025-05-27
• Study First Submitted: 2025-05-28
• Study First Submitted QC: 2025-05-28
• Last Update Submitted: 2025-05-28
• Study First Posted: 2025-06-05
• Last Update Posted: 2025-06-05
• Primary Completion: 2025-12-14
• Study Completion: 2025-12-14

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 165

Inclusion Criteria

• patients who were diagnosed SMCs or HCM. Gene testing and muscle biopsy were used to confirm the diagnosis of SMCs. The diagnose of HCM was according to the 2024 ESC Guidelines of HCM but without evidence of SMCs.
• complete baseline data
• accessible follow-up data

Exclusion Criteria

• incomplete baseine data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
primary outcome	3 years	a composite of all-cause death, hospitalization for heart failure, myocardial infarction, ischemia or hemorrhagic stroke (excluding transient ischemic attack), other thrombotic events, and modified International Society on Thrombosis and Haemostasis crit

Trial Locations

Locations (1)

Fuwai Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, China